Modality
Nanobody
MOA
Anti-Tau
Target
WRN
Pathway
Amyloid
GISTLGSIPF
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
→ Dec 2026
Phase 1Current
NCT03113592
359 pts·GIST
2022-06→2025-08·Active
NCT03222568
2,557 pts·LGS
2017-05→2026-12·Completed
2,916 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-038mo agoInterim· GIST
2026-12-078mo awayInterim· LGS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Interim
2025-08-03 · 8mo ago
GIST
Interim
2026-12-07 · 8mo away
LGS
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03113592 | Phase 1 | GIST | Active | 359 | Biomarker |
| NCT03222568 | Phase 1 | LGS | Completed | 2557 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA |